Table S3 from Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer

作者：Qin Xu, Zhengrong Deng, Jing Liu, Yanhong Zhuo, Fei Zhu, Lele Chang, Qin Liu, Yajuan Fu, Peiwei Li, yunyun liu, Songhua Huang, Li Li, Xingyun Xie, Ying Chen, Yingtao Lin, Lele Zang, Meifang Ke, Li Chen, Xiaoxia Huang, Cong Wang, Yanhong Wang, Yaxin Kang, Yuqin Wang, Mingxuan Zhu, Huiqi Zhang, Zhixin Wang, Peidong Zhang, Dan Hu, Huaiwu Lu, Yang Sun, Shengtao Zhou · 年份：2026 · DOI：10.1158/2159-8290.31443176 · 研究领域：Endometrial and Cervical Cancer Treatments、Cancer Immunotherapy and Biomarkers、Lung Cancer Research Studies

<p>Table. S3. Treatment-related adverse events in the safety population (events occurring in ≥10% of participants)</p>